Summary
This study will help find the most suitable dose of ASP546C in people with gastric
cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific
solid tumors. GEJ is where the food pipe (esophagus) joins the stomach.
This study is in 2 parts. In both parts of the study, ASP546C will be given once in
3-week cycles. It will be given slowly through a tube into a vein. This is called an
infusion.
In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an
infusion of either a higher dose or a lower dose of ASP546C.
In Part 2, people with pancreatic cancer or who have one of the other solid tumors can
take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in
this part of the study will receive an infusion of the higher dose of ASP546C.
People will visit the clinic on certain days to receive ASP546C and have health checks.
The number of visits and checks done during the study will depend on the health of each
person and whether they are still receiving infusions of ASP546C.